Hattori K, Sakata‐Yanagimoto M, Kusakabe M, et al. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Sci. 2019;110:401--407. 10.1111/cas.13848

1. INTRODUCTION {#cas13848-sec-0001}
===============

Primary central nervous system lymphoma (PCNSL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) that arises within the brain or eyes.[1](#cas13848-bib-0001){ref-type="ref"} Recent exome sequencing studies have shown that genes of the Toll‐like receptor and B‐cell receptor signaling pathways are frequently mutated in PCNSL.[2](#cas13848-bib-0002){ref-type="ref"}, [3](#cas13848-bib-0003){ref-type="ref"}, [4](#cas13848-bib-0004){ref-type="ref"} Notably, the hotspot mutation of *MYD88*, which results in the conversion from leucine to proline at the 265th position (L265P *MYD88* mutation), has a very high prevalence in patients with PCNSL (38%‐85.4%).[2](#cas13848-bib-0002){ref-type="ref"}, [3](#cas13848-bib-0003){ref-type="ref"}, [4](#cas13848-bib-0004){ref-type="ref"}, [5](#cas13848-bib-0005){ref-type="ref"}

A previous report showed that the L265P *MYD88* mutation, but not other mutations, found in PCNSL tumors was detected in peripheral blood mononuclear cells (PBMNC).[3](#cas13848-bib-0003){ref-type="ref"} This may imply that the L265P *MYD88* mutation may occur at the extra‐central nervous system (CNS) compartment as the initial genetic event for PCNSL development. However, the actual developmental process of PCNSL should be examined from a different point of view.

Comparisons between genomic alterations in tumors at diagnosis and those at relapse led to the suggestion of common precursor cells (CPC) for the primary and relapsed tumors in other types of lymphoma such as follicular lymphomas (FL) and mantle cell lymphomas (MCL).[6](#cas13848-bib-0006){ref-type="ref"}, [7](#cas13848-bib-0007){ref-type="ref"} Primary and relapsed tumors of FL and MCL may arise through a divergent evolution pattern from CPC by acquiring mutations specific to either primary or relapsed tumors.[6](#cas13848-bib-0006){ref-type="ref"}, [7](#cas13848-bib-0007){ref-type="ref"} PCNSL recurs within the CNS in most relapsed cases, whereas extra‐CNS relapse (systemic relapse) is experienced in \<7% of the relapsed cases.[1](#cas13848-bib-0001){ref-type="ref"} The present study aimed at identifying the presence of CPC with multiple mutations by examining paired primary intra‐ and relapsed extra‐CNS tumors and further assessing the initiating events by examining *MYD88* mutations in bone marrow mononuclear cells (BMMNC).

2. MATERIALS AND METHODS {#cas13848-sec-0002}
========================

2.1. Targeted deep sequencing by Ion Torrent PGM {#cas13848-sec-0003}
------------------------------------------------

Targeted deep sequencing (TDS) was carried out in five paired primary intra‐CNS and relapsed extra‐CNS tumors and BMMNC using the Lymphopanel for 34 candidate genes[8](#cas13848-bib-0008){ref-type="ref"} and our in‐house PCNSL panel for 12 candidate genes[1](#cas13848-bib-0001){ref-type="ref"} ([\[Link\]](#cas13848-sup-0005){ref-type="supplementary-material"}, [\[Link\]](#cas13848-sup-0006){ref-type="supplementary-material"}). Because seven genes overlapped, 39 candidate genes were analyzed in total. The mutational profiles of five primary intra‐CNS tumors by our in‐house PCNSL panel were previously described.[1](#cas13848-bib-0001){ref-type="ref"} Both panels were designed by custom Ampliseq Designer system (Thermo Fisher Scientific, Waltham, MA, USA). Libraries were prepared from 5 ng tumor DNAs using the Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific), according to the manufacturer\'s instructions. Sequencing was carried out using Ion 318 chips on Ion Torrent Personal Genome Machine (PGM) (Thermo Fisher Scientific). Data were analyzed by carrying out alignment with the hg19 human reference genome and variant calling was done with Variant Caller 5.2 (Thermo Fisher Scientific). Single nucleotide variants or insertions/deletions with frequencies of 3% or more were considered candidate mutations. These mutations were validated by genomic PCR followed by Sanger sequencing. The primers are listed in [Table S3](#cas13848-sup-0007){ref-type="supplementary-material"}.

2.2. Polymerase chain reaction detection of complementarity‐determining region 3 region of Ig heavy chain genes {#cas13848-sec-0004}
---------------------------------------------------------------------------------------------------------------

Polymerase chain reaction (PCR) for amplification of the complementarity‐determining region 3 (CDR3) was carried out in a semi‐nested approach.[9](#cas13848-bib-0009){ref-type="ref"} The first step of PCR was carried out using primer FR2A or FR3A plus a reverse primer directed at the joining region (LJH). In the second step, the same forward primer (FR2A or FR3A) was used in mixtures with an inner reverse primer VLJH. The following primers were used: FR2A, TGGRTCCGMCAGSCYYCNGG; FR3A, ACACGGCYSTGTATTACTGT; LJH, TGAGGAGACGGTGACC; VLJH, GTGACCAGGGTNCCTTGGCCCCAG. In both steps, the PCR mixture contained TaKaRa Taq reagents (Takara, Shiga, Japan). The first PCR (35 cycles) contained 100 ng DNA and the second PCR (20 cycles) contained 1 μL of the undiluted first PCR product. The standard PCR cycle condition of the first step consisted of denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds. The PCR cycle of the second step consisted of denaturation at 94°C for 10 seconds, annealing at 55°C for 10 seconds, and extension at 72°C for 10 seconds. These reactions were preceded by an initial denaturation step at 94°C for 5 minutes and concluded by a final extension at 72°C for 7 minutes. PCR products (10 μL) were analyzed on 3% agarose gel stained with ethidium bromide by electrophoresis and viewed under ultraviolet light. Additionally, to improve resolution, PCR products were also run on acrylamide gel.

PCR amplicons were extracted by using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced by direct sequencing. Obtained sequences were analyzed using IMGT/V‐QUEST from the international ImMunoGeneTics information system (IMGT) (<http://www.imgt.org>).[10](#cas13848-bib-0010){ref-type="ref"}

3. RESULTS {#cas13848-sec-0005}
==========

3.1. Clinical features and quality evaluation of tumor samples {#cas13848-sec-0006}
--------------------------------------------------------------

Clinical and histological findings of five PCNSL patients who experienced extra‐CNS relapse are summarized in [\[Link\]](#cas13848-sup-0008){ref-type="supplementary-material"}, [\[Link\]](#cas13848-sup-0009){ref-type="supplementary-material"}. In all five patients, first complete response (CR) was achieved during or at the end of the modified European Organisation for Research and Treatment of Cancer (EOTRC) chemotherapy for PCNSL[4](#cas13848-bib-0004){ref-type="ref"} and was maintained for more than 1 year ([Figure S1](#cas13848-sup-0001){ref-type="supplementary-material"}). Subsequently, extra‐CNS relapse occurred ([Figure S1](#cas13848-sup-0001){ref-type="supplementary-material"}). Median time from diagnosis of PCNSL to extra‐CNS relapse was 18 months ([Table S4](#cas13848-sup-0008){ref-type="supplementary-material"}). Sites of extra‐CNS relapse were maxillary sinus and submandibular lymph nodes in patient T1, intra‐abdominal lymph nodes and subcutaneous tissue of back in T2, subcutaneous tissue of right thigh in T5, left breast, and left supraclavicular and intra‐abdominal lymph nodes in TP39, and subcutaneous tissue of lower back and submandibular lymph nodes in TP44 ([Table S4](#cas13848-sup-0008){ref-type="supplementary-material"}). All five patients had no detectable lesions in the CNS at the time of diagnosis of extra‐CNS relapse. However, in one patient (patient T1), magnetic resonance imaging (MRI) findings confirmed CNS relapse in the left frontal lobe and the left optic nerve 1 month after diagnosis of extra‐CNS relapse ([Figure S1](#cas13848-sup-0001){ref-type="supplementary-material"}). Tumor cell content of each primary intra‐CNS and relapsed extra‐CNS tumor sample varied from 1.09% to 90% in flow cytometric or histological analysis ([Table S6](#cas13848-sup-0010){ref-type="supplementary-material"}). Quality of the extracted DNA from tumor samples was described as ΔΔCT based on the results of real‐time quantitative PCR by using Agilent FFPE QC Kit (Agilent, Wilmington, USA) ([Data S1](#cas13848-sup-0016){ref-type="supplementary-material"}). ΔΔCT of paired tumor samples varied from 0.01 to 0.76 ([Table S7](#cas13848-sup-0011){ref-type="supplementary-material"}).

3.2. Recurrently mutated genes in PCNSL patients {#cas13848-sec-0007}
------------------------------------------------

Targeted deep sequencing was carried out for 39 genes in five tumor pairs using the Lymphopanel[8](#cas13848-bib-0008){ref-type="ref"} and our in‐house PCNSL panel.[4](#cas13848-bib-0004){ref-type="ref"} Mean coverages in each panel were 1593 × (range, 370‐3099) and 1563 × (range, 1084‐1990), respectively. In primary intra‐CNS tumors, 61 probable somatic mutations were identified including 53 nonsilent single nucleotide variants (SNV), seven deletions, and one insertion. Recurrent gene mutations were found in these such as *MYD88* (4/5), *CD79B* (4/5), *PIM1* (3/5), *KMT2D* (3/5), and *GNA13* (3/5). The mutation profile of intra‐CNS tumors in our study was consistent with that of PCNSL in a previous report, in which the same Lymphopanel was used.[11](#cas13848-bib-0011){ref-type="ref"} In relapsed extra‐CNS tumors, 68 probable somatic mutations were identified including 57 nonsilent SNV, eight deletions, and three insertions. Genes such as *MYD88* (4/5), *CD79B* (3/5), *PIM1* (4/5), *KMT2D* (3/5), and *PRDM1* (3/5) were recurrently mutated (Figure [1](#cas13848-fig-0001){ref-type="fig"}; [Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}). An aberrant somatic hypermutation (aSHM) indicator value was calculated according to the algorithm of Khodabakhshi et al.[13](#cas13848-bib-0013){ref-type="ref"} The value was lower than 0.1, showing that *PIM1* mutations were associated with aSHM ([Data S1](#cas13848-sup-0016){ref-type="supplementary-material"}, [Table S9](#cas13848-sup-0013){ref-type="supplementary-material"}).[12](#cas13848-bib-0012){ref-type="ref"}

![Recurrently mutated genes with primary central nervous system lymphoma (PCNSL). Comparison of mutated genes between primary or relapsed extra‐central nervous system tumors of PCNSL. Numbers of mutations are indicated when more than one mutation was detected in the genes](CAS-110-401-g001){#cas13848-fig-0001}

3.3. Landscape of somatic mutations in primary intra‐ and relapsed extra‐CNS tumors of PCNSL patients {#cas13848-sec-0008}
-----------------------------------------------------------------------------------------------------

We found shared mutations in all five paired tumors and unique mutations in all five intra‐CNS tumors and in four out of five extra‐CNS tumors (Figure [2](#cas13848-fig-0002){ref-type="fig"}). In total, 16 mutations in 11 genes were found to be shared (Figures [2](#cas13848-fig-0002){ref-type="fig"} and [3](#cas13848-fig-0003){ref-type="fig"}; [Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}). *MYD88* (4/5) mutations, L265P in three and P258L in one, were the most recurrently shared mutations. *CD79B* (3/5), *KMT2D* (3/5), and *PIM1* (2/5) mutations also emerged as recurrently shared mutations, among which Y196 *CD79B* (3/5), and Q2951R *KMT2D* (2/5) were identified as hotspot mutations (Figure [1](#cas13848-fig-0001){ref-type="fig"}, [Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}). Forty‐five mutations in six genes, including recurrent *GNA13* and *CREBBP* mutations were specific to primary intra‐CNS tumors. (Figures [2](#cas13848-fig-0002){ref-type="fig"} and [3](#cas13848-fig-0003){ref-type="fig"}; [Figure S2](#cas13848-sup-0002){ref-type="supplementary-material"}, [Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}). Fifty‐two mutations in six genes were specific to relapsed extra‐CNS tumors (Figures [2](#cas13848-fig-0002){ref-type="fig"} and [3](#cas13848-fig-0003){ref-type="fig"}; [Figure S2](#cas13848-sup-0002){ref-type="supplementary-material"}, [Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}).

![Number of somatic variants in each primary central nervous system (CNS) lymphoma tumor sample. Targeted deep sequencing for 39 genes was carried out for five paired tumors. Number of mutations found in both tumors (shared mutations), those specific to primary intra‐CNS tumors, and those specific to extra‐CNS tumors is indicated](CAS-110-401-g002){#cas13848-fig-0002}

![Overlaps in genes and somatic mutations discovered in intra‐ and extra‐central nervous system (CNS) tumors. Venn diagram shows the comparison of genes and mutations between five intra‐ and extra‐CNS tumor samples (A) Mutated genes shared between intra‐ and extra‐CNS tumors were shown in overlap of the venn diagram. Detail of shared mutated genes were written under "Common genes". (B) Somatic mutations shared between intra‐ and extra‐CNS tumors were shown in overlap of the venn diagram. Detail of shared mutations were written under "Common mutations".](CAS-110-401-g003){#cas13848-fig-0003}

3.4. Divergent evolution of primary intra‐ and relapsed extra‐CNS tumors from a CPC {#cas13848-sec-0009}
-----------------------------------------------------------------------------------

These distribution patterns of shared and separated mutations strongly indicated the presence of CPC that precedes the development of primary intra‐CNS tumors. To seek the localization of the CPC in the B‐lineage cell differentiation map, *IgH* rearrangement status of paired tumors was examined in paired tumors of patients T1, T5, and TP39 (Figures [4](#cas13848-fig-0004){ref-type="fig"} and [5](#cas13848-fig-0005){ref-type="fig"}). PCR products of the CDR3 region of *IgH* showed a single sharp band the same size in both intra‐ and extra‐CNS tumors of patient T1 (Figure [4](#cas13848-fig-0004){ref-type="fig"}). Direct sequencing of the clonal bands confirmed that both tumors shared identical CDR3 sequences (Figure [4](#cas13848-fig-0004){ref-type="fig"}). In contrast, multiple bands were observed in the intra‐CNS tumors of patient T5 and TP39, whereas the extra‐CNS tumor of each patient appeared to have a single band (Figure [5](#cas13848-fig-0005){ref-type="fig"}). CDR3 sequences of both extra‐CNS and intra‐CNS tumors of patients T5 and TP39 could not be determined by direct sequencing. Then, the PCR products were cloned into a plasmid and each clone recovered from *Escherichia coli* colonies was sequenced to determine the clonality. Variable regions of *IgH* (VH) were derived from either the V~H~3 or V~H~4 family in both tumors of T5 ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}). Nevertheless, the CDR sequences were mostly mapped to the VH genes of the V~H~3 family (V~H~3‐23\*04, V3‐72\*01, or V3‐30‐3\*03) in the intra‐CNS tumor, whereas V~H~4‐4\*07 of the V~H~4 family was dominant in the extra‐CNS tumor (intra‐CNS tumor, V~H~3 16/18 \[89%\] vs V~H~4 2/18 \[11%\]; extra‐CNS tumor, V~H~3 3/17 \[18%\] vs V~H~4 14/17 \[82%\]) ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}). In TP39, VH were derived from the V~H~4‐4\*07 of the V~H~4 family in the intra‐CNS tumor, whereas V~H~3‐21\*01 of the V~H~3 family was detected in the extra‐CNS tumor (intra‐CNS tumor, V~H~3 1/17 \[6%\] vs V~H~4 16/17 \[94%\] extra‐CNS tumor, V~H~3 18/18 \[100%\] vs V~H~4 0/100 \[0%\]) ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}). Homology with the germline sequence and usage of V~H~‐D~H~‐J~H~ genes are summarized in [Table S10](#cas13848-sup-0014){ref-type="supplementary-material"} and [Figure S3](#cas13848-sup-0003){ref-type="supplementary-material"}. Predominantly repeated or similar clones with identical V‐D‐J usage were identified in all tumor samples. In T5 intra‐CNS tumor, clones with V~H~3‐23\*01/D~H~4‐23\*01/J~H~6\*02 rearrangement and those with V~H~3‐72\*01/D~H~6‐25\*01/J~H~6\*03 rearrangement were identified dominantly in 4/18 \[22%\] and 4/18 \[22%\] ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}). In T5 extra‐CNS tumor, clones with V~H~4‐4\*07/D~H~5‐24\*01/J~H~4\*01 were dominantly identified in 14/17 \[82%\], in TP39 intra‐CNS tumor, those with V~H~4‐4\*07/D~H~5‐24\*01/J~H~4\*01 in 16/17 \[94%\] and in TP39 extra‐CNS tumor, those with V~H~3‐21\*01/D~H~6‐19\*01/J~H~4\*01 in 15/18 \[83%\] ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}). Almost all V~H~ were highly mutated (T5 intra‐CNS tumor, 17/18; T5 extra‐CNS tumor, 14/17; TP39 intra‐CNS tumor, 16/17; TP39 extra‐CNS tumor, 18/18) presumably because of ongoing hypermutation[13](#cas13848-bib-0013){ref-type="ref"}, [14](#cas13848-bib-0014){ref-type="ref"}, [15](#cas13848-bib-0015){ref-type="ref"}, [16](#cas13848-bib-0016){ref-type="ref"} ([Table S10](#cas13848-sup-0014){ref-type="supplementary-material"}, [Figure S3](#cas13848-sup-0003){ref-type="supplementary-material"}).

![*IgH* rearrangement status of paired tumors in patient T1. (A) Photographs of PCR gels and (B) the electropherogram of direct sequencing show the *IgH* rearrangement status of paired tumors in patient T1. CNS, central nervous system](CAS-110-401-g004){#cas13848-fig-0004}

![PCR analysis of *IgH* rearrangement status of paired tumors in patients T5 and TP39. Photographs of PCR gels show the *IGH* rearrangement status of paired tumors in patients T5 and TP39. CNS, central nervous system](CAS-110-401-g005){#cas13848-fig-0005}

These analyses imply that the CPC is mapped at distinct positions in B‐lineage differentiation; the position after *IgH* rearrangement and even after hypermutation at the variable region was suggested in T1, whereas emergence of CPC before *IgH* rearrangement was suggested in T5 and TP39.

3.5. Detection of L265P *MYD88* mutations in BMMNC or PBMNC with droplet digital PCR {#cas13848-sec-0010}
------------------------------------------------------------------------------------

To further characterize the initiation of PCNSL that is theorized to precede the emergence of CPC, we analyzed PBMNC of T1 collected at the diagnosis of extra‐CNS relapse and BMMNC of T1, T2, T5 and 20 PCNSL patients in an extended cohort collected at diagnosis (N = 24). These 24 cases were those in whom the L265P *MYD88* mutations were identified in primary PCNSL tumors. According to the pathological diagnosis, no clinical evidence of lymphoma infiltration was found in the bone marrow (BM) of these patients. The L265P *MYD88* mutations were identified in PBMNC (T1) and in nine out of 23 BMMNC (in total, 10 of 24) by droplet digital PCR (ddPCR), whereas the mutations were not detected in any of the samples by TDS, a less sensitive method ([Figure S4](#cas13848-sup-0004){ref-type="supplementary-material"}, [Table S11](#cas13848-sup-0015){ref-type="supplementary-material"}).

4. DISCUSSION {#cas13848-sec-0011}
=============

This is the first multidimensional study of mutational dynamics comparing mutational profiles between intra‐CNS tumors and extra‐CNS tumors. In our study, all the five paired tumors shared multiple mutations. Unique somatic mutations were observed in all the five intra‐CNS tumors and four out of five extra‐CNS tumors ([Table S8](#cas13848-sup-0012){ref-type="supplementary-material"}, [Figure S2](#cas13848-sup-0002){ref-type="supplementary-material"}). Among the somatic mutations specific to intra‐CNS tumors, *TBL1XR1* mutation was reported to be more prevalent in PCNSL than in DLBCL not otherwise specified (NOS).[17](#cas13848-bib-0017){ref-type="ref"} In contrast, a *SOCS1* mutation was detected in the tumor of subcutaneous tissue in TP44 ([Table S4](#cas13848-sup-0008){ref-type="supplementary-material"}). *SOCS1* mutations are known to be more prevalent in primary cutaneous diffuse large B‐cell lymphoma, leg type compared to DLBCL NOS.[18](#cas13848-bib-0018){ref-type="ref"} Therefore, somatic mutations in these genes may bias the location of tumors. These results suggest that the paired tumors originate from divergent evolution of CPC through accumulation of distinct mutations.

Recent studies have proposed that primary and relapsed tumors in several hematological cancers may arise from CPC.[6](#cas13848-bib-0006){ref-type="ref"}, [7](#cas13848-bib-0007){ref-type="ref"}, [18](#cas13848-bib-0018){ref-type="ref"}, [19](#cas13848-bib-0019){ref-type="ref"}, [20](#cas13848-bib-0020){ref-type="ref"} Previously, it was reported that the dominant clones were identical in paired tumors of primary and relapsed MCL and FL according to the VDJ coding joints, suggesting that CPC may arise after VDJ rearrangement (Figure [6](#cas13848-fig-0006){ref-type="fig"}).[6](#cas13848-bib-0006){ref-type="ref"}, [7](#cas13848-bib-0007){ref-type="ref"} In contrast, in a part of Richter syndrome, distinct *IgH* clones were observed between aggressive lymphomas and primary chronic lymphocytic leukemia (CLL) tumors suggesting that divergence may occur before the VDJ rearrangements.[19](#cas13848-bib-0019){ref-type="ref"}, [20](#cas13848-bib-0020){ref-type="ref"} In the current study, the existence of identical monoclonal B‐cell clones in both intra‐ and extra‐CNS tumors of T1 suggests that divergence from CPC could occur after the point of *IgH* rearrangement, similar to the case of FL and MCL (Figure [6](#cas13848-fig-0006){ref-type="fig"}). In contrast, distinct *IgH* clones were observed in the intra‐ and extra‐CNS tumors of patients T5 and TP39, which suggests that divergence of CPC could occur preceding a VDJ rearrangement in BM, similar to the case of Richter syndrome in CLL (Figure [6](#cas13848-fig-0006){ref-type="fig"}).[19](#cas13848-bib-0019){ref-type="ref"}, [20](#cas13848-bib-0020){ref-type="ref"} In a previous analysis, tumor‐related *IgH* clones were detected in blood and bone marrow of three PCNSL patients.[21](#cas13848-bib-0021){ref-type="ref"} These results suggest that divergence from the CPC could occur after the point of *IgH* rearrangement in all of these patients, although hypermutations occurred independently in *IgH* clones of primary tumors in the CNS and in those in the systemic sites.[21](#cas13848-bib-0021){ref-type="ref"} This pattern is similar to the case of patient T1 in our study in which identical monoclonal B‐cell clones existed in both intra‐ and extra‐CNS tumors, although independent hypermutations were not observed in these tumors. In contrast, the findings in patients T5 and TP39 were remarkable because VDJ usage was different between intra‐ and extra‐CNS tumors in these two patients.

![Stages of divergence from common precursor cells to tumors. Black arrows indicate the clonal pathway between samples. CLL, chronic lymphocytic leukemia; CNS, central nervous system; FL, follicular lymphoma; MCL, mantle cell lymphoma; PCNSL, primary central nervous system lymphoma](CAS-110-401-g006){#cas13848-fig-0006}

It has been suggested that, in FL and MCL, the initial genetic events may occur in pre‐B stage of differentiation during the recombination of the VDJ segments in the BM because the tumor cells harbor *IgH* fusions with other genes: *IgH/BCL2* in FL and *IgH/CCND1* in MCL. In several types of lymphomas, the initiating events could be tracked back even to hematopoietic stem/progenitor cells upstream of the lineage commitment towards either B cells or T cells: *NOTCH1* and *SF3B1* mutations in CLL,[22](#cas13848-bib-0022){ref-type="ref"} *BRAF* mutations in hairy cell leukemia[23](#cas13848-bib-0023){ref-type="ref"} and *TET2/DNMT3A* mutations in angioimmunoblastic T‐cell lymphomas.[24](#cas13848-bib-0024){ref-type="ref"}, [25](#cas13848-bib-0025){ref-type="ref"}, [26](#cas13848-bib-0026){ref-type="ref"} Frequent detection of L265P *MYD88* mutation in BM suggests that, in PCNSL patients, this mutation may occur before or during the B‐cell differentiation process before the cells leave the BM environment and migrate to the peripheral lymphoid organs as naïve mature B lymphocytes. This theory, however, needs further proof because the presence of minimal contamination of lymphoma cells in the BM was not completely excluded in our study, although the presence of lymphoma cells was excluded by immunohistochemical evaluation and flow cytometry. Additionally, we were unable to examine the L265P *MYD88* mutation in healthy individuals. The L265P *MYD88* mutation was detected in PBMNC of only one subject at a mutation allele frequency of 23% in a cohort of 12 380 patients with psychiatric disease.[27](#cas13848-bib-0027){ref-type="ref"} This mutation was undetected in that of any subject in another large cohort of 17 182 individuals without hematological malignancies.[28](#cas13848-bib-0028){ref-type="ref"} Because the cutoff levels of mutation allele frequencies in both studies were 2%, smaller allele frequencies could have escaped detection and, therefore, the possibility cannot be completely excluded that very few cells with L265P *MYD88* are present even in healthy individuals.

In conclusion, our data suggest that intra‐ and extra‐CNS tumors might originate from the CPC in PCNSL. The initial event could be a mutation in the *MYD88* gene, and the emergence of CPC might follow by acquisition of subsequent genetic alterations. Precise clarification of these steps may contribute to establishing more robust biomarkers and therapeutic approaches with newly developed targeted drugs.
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